BioNTech SE Files Form 6-K with SEC

TL;DR

BioNTech filed a 6-K on April 2, 2025, confirming a December 23, 2024 term sheet.

AI Summary

BioNTech SE announced on April 2, 2025, that it entered into a binding term sheet on December 23, 2024. The filing is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC.

Why It Matters

This filing indicates ongoing corporate activities and disclosures by BioNTech SE to the U.S. Securities and Exchange Commission, providing transparency to investors.

Risk Assessment

Risk Level: low — The filing is a routine SEC disclosure for a foreign private issuer and does not contain new material financial or operational information.

Key Players & Entities

• BioNTech SE (company) — Registrant
• December 23, 2024 (date) — Date of Term Sheet
• April 2, 2025 (date) — Filing Date

FAQ

From the Filing

0001776985-25-000017.txt : 20250402 0001776985-25-000017.hdr.sgml : 20250402 20250402161651 ACCESSION NUMBER: 0001776985-25-000017 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250402 FILED AS OF DATE: 20250402 DATE AS OF CHANGE: 20250402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 25804765 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kpennagreements2apr2.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ INFORMATION INCLUDED AS PART OF THIS FORM 6-K BioNTech SE (the “Company”) previously disclosed that on December 23, 2024, the Company entered into a binding term sheet (the “Term Sheet”) with the University of Pennsylvania (“Penn”) to provide terms on which the Company would retain license rights under certain Penn patent rights in order to allow it to continue to pursue development and commercialization of Licensed Products (as defined in the Patent Sublicense Agreement entered into between the Company and Cellscript LLC as of July 19, 2017 (the “PSA”)). On March 27, 2025, the Company and Penn entered into a series of agreements pursuant to the Term Sheet, including (i) a Settlement Agreement, pursuant to which the Company shall, among other things, pay up to $467.0 million to Penn, as previously disclosed, consisting of $400.0 million as royalties for calendar years 2020-2023, up to $15.0 million in funding for a three-year extension of the research term of the Company’s and Penn’s vaccine alliance, and $52.0 million as a contribution to a research and development investment fund (the “Fund”) to be jointly managed by the Company and Penn&#59; and (ii) a side letter to the PSA to provide for a low single-digit percentage royalty on Net Sales of Licensed Products (each as defined in the PSA) for 2024 onwards and provide a framework for a license for use in combination products which would include the COVID-19 vaccine used in combination with other active pharmaceutical ingredients. The Company and Penn have also aligned on principal terms on which the Fund will be established and managed. The Company and Penn additionally entered into amendments to (i) their existing Collaboration & License Agreement dated October 9, 2018, including the three-year extension of the research term, in connection with which the Company shall provide additional funding of up to $15.0 million as discussed above, and (ii) their existing Collaboration & License Agreement dated January 18, 2023, each as amended and or/supplemented to date. The Company’s execution of the Settlement Agreement does not in a